Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022
We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202
